RxDoctor Payments Data

Sarah Garrott, NP

Nurse Practitioner · Springfield, MONPI 1649515917

Payments from drug & device makers

$7,213in general payments, 2019–2025

Across 386 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$912
  • Johnson & Johnson$837
  • Gilead$775
  • Intercept Pharmaceuticals, Inc.$386
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$353
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$7,17499%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,213 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$20,812
Medicare patients
212
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin61$215,780
Humira PenAdalimumab14$95,362
LinzessLinaclotide72$59,505
RezdiffraResmetirom11$51,246
CreonLipase/Protease/Amylase20$25,672
MovantikNaloxegol Oxalate11$13,063
Mesalamine19$12,147
MotegrityPrucalopride Succinate12$6,203
Ursodiol21$3,409
Mesalamine ErMesalamine13$2,868
Lactulose43$2,381
Lubiprostone26$2,009
Sucralfate20$1,910
Colesevelam Hcl16$1,833
Budesonide DrBudesonide13$1,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$353$215,78061 claims
AbbVieLinzess, Creon$2,591$85,17792 claims
Madrigal PharmaceuticalsRezdiffra$184$51,24611 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$912$6,20312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →